Given the rarity and near mutual exclusivity of TRAF7 mutations, future clinical trials can be enhanced through spatial–genomic stratification to heighten biomarker specificity, reduce intertumoral heterogeneity, and enable rational introduction of synthetic lethal or pathway-specific therapies for mesoderm-derived skull base meningiomas. The gene discussed is TRAF7; the disease is skull base meningioma.